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N-Acetylcysteine has been used for 
treatment or prophylaxis of several dis-
tinct diseases that are associated with 
increased oxidative stress.9 Th is thiol-
containing antioxidant was used to treat 
a variety of pulmonary diseases and to 
ameliorate the toxic eff ects in a variety 
of experimentally or clinically induced 
ischemia–reperfusion syndromes of the 
heart, kidney, and liver.9 Furthermore, 
N-acetylcysteine causes vasodilatation 
in particular by enhancing the eff ects 
of nitric oxide, and it inhibits platelet 
aggregation. Because of its antioxida-
tive properties, N-acetylcysteine therapy 
has been used in unstable angina, acute 
myocardial infarction, heart failure, 
hypertension, and paracetamol poison-
ing, and in critically ill patients with 
sepsis, although with variable results. 
Finally, N-acetylcysteine is oft en used 
to prevent contrast-induced nephropa-
thy. However, at present there is limited 
evidence that acetylcysteine together 
with adequate hydration may be useful 
as standard prophylactic procedure in 
patients with a high risk for contrast-
induced nephropathy.10
Th e study by Feldman et al.4 describes 
a novel application of N-acetylcysteine, 
which is cheap and without major 
side effects. If their results are con-
fi rmed in additional studies, the oral 
administration of 600 mg N-acetyl-
cysteine twice daily may help to prevent 
aminoglycoside-induced hearing loss in 
daily practice.
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Table 1 | Postulated mechanisms of 
N-acetylcysteine to reduce oxidative 
stress
1.  Redox mechanism: Increase of cysteine, an 
antioxidant that can be oxidized to cystine
2.  Redox mechanism: Increase of glutathione 
(γ-glutamyl-cysteinyl-glycine; GSH), an 
antioxidant that can be oxidized to GSSG
3.  Formation of mixed disulfides with free 
sulfhydryl (SH) groups of cellular peptides
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A fat chance of renal injury
MP Koeners1 and JA Joles1
Williams et al. demonstrate in sheep that juvenile obesity per se 
leads to renal pathology but that prenatal undernutrition effectively 
abolishes any renal pathology associated with juvenile obesity. These 
peculiar findings are quite opposite to what has been documented in 
many epidemiological and animal studies. They provoke questions 
about how adverse developmental conditions can either support 
or compromise adaptation to excess nutrient intake and low motor 
activity later in life.
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William Shakespeare relates overweight 
and life expectancy in Henry IV, Part 
II. The king warns a “surfeit-swell’d” 
Falstaff : 
Make less thy body hence, and more thy 
grace; 
Leave gormandising; know the grave doth 
gape
For thee thrice wider than for other men.
Analogous recent literature suggests a 
relation between obesity and renal dis-
ease, and encourages weight loss, because 
this oft en leads to a reduction in pro-
teinuria.1,2 However, even though a lot 
of data suggest a linear relation between 
body mass index and proteinuria, the 
mechanisms involved remain elusive. 
Of course, most obese subjects do not 
develop renal disease. Hence, there must 
be other factors associated with obesity 
that lead to renal disease. Knowledge of 
these factors is important, because it will 
help us to counsel and treat overweight 
patients more effectively than simply 
recommending weight loss. Weight 
loss, although initially relatively easy, 
is hard to maintain. Even when main-
tained, weight loss might not always be 
the panacea that it is oft en considered 
to be.
Obese individuals oft en demonstrate 
hyperfiltration,3 and angiotensin-
converting enzyme inhibition is very 
eff ective in reducing their proteinuria.1 
Recently, drastic weight loss aft er bari-
atric surgery in morbidly obese patients 
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induced parallel reductions in body mass 
index, glomerular filtration rate, and 
proteinuria.4 Hence, hyperfi ltration has 
frequently been advanced as an underly-
ing mechanism,1 the assumption being 
that hyperfi ltration refl ects increased 
glomerular capillary pressure. How-
ever, classic single-nephron stop-fl ow 
pressure measurements in obese Zucker 
rats failed to document glomerular 
hypertension.5 Moreover, a peroxisome 
proliferator-activated receptor-γ agonist, 
angiotensin-converting enzyme inhibi-
tion, and their combination markedly 
reduced proteinuria in this model with-
out signifi cant reductions in glomerular 
fi ltration rate or glomerular capillary 
pressure.6 Th us, although the discussion 
is by no means closed, nonhemodynamic 
mechanisms have been proposed.2
Adipose tissue itself is a rich source 
of potential troublemakers.2 Besides 
angiotensinogen and renin, it produces 
cytokines (tumor necrosis factor-α, 
interleukin-6), growth factors (plasmino-
gen activator inhibitor-15, transforming 
growth factor-β), and the peptide hor-
mone leptin. Leptin has many growth-
promoting and proliferative eff ects in the 
kidney, and leptin infusion can induce 
glomerulosclerosis in rats.2 Leptin resist-
ance is common in obesity, resulting 
in high leptin levels that can increase 
sympathetic activity, which is known to 
be high in insulin resistance and obes-
ity. However, extra-adipocyte leptin 
release, especially from the brain, is also 
increased in human obesity and may well 
contribute to the enhanced sympathetic 
drive.7 In obese Zucker rats, renal injury 
can be ameliorated pharmacologically 
with a peroxisome proliferator-acti-
vated receptor-γ agonist, even though 
this intervention more than doubled 
body weight.6 Th us, in some obese indi-
viduals, simply reducing weight in order 
to reduce adipose tissue may not be an 
adequate solution. A challenging study 
by Williams et al.8 (this issue) now fur-
ther questions the pathogenic role of 
increased blood pressure, hyperfi ltration, 
hyperleptinemia, hyperglycemia, and 
even obesity as such, in the pathogenesis 
of obesity-related renal injury.8
As is mentioned above, there must be 
other factors that predispose some obese 
individuals to renal disease. One of these 
may be a disturbance in renal develop-
ment. It is well known that symptoms of 
the metabolic syndrome are more severe 
in individuals who have been exposed to 
a perturbation during development, be it 
nutritional, environmental, pharmaceu-
tical, or in the uteroplacental circula-
tion.9 Following up on previous studies, 
Williams et al.8 exposed sheep dams to 
a 50% nutrient restriction from day 30 
to day 80 of gestation (gestation in sheep 
lasts nearly 6 months), as compared with 
control dams who received a diet with 
an energy content of 7 megajoules per 
day. Th ereaft er all dams received a diet 
adjusted to 100% metabolizable energy 
until weaning of the lambs at 10 weeks of 
age. From weaning to 12 months of age, 
the lambs were either group-housed in a 
barn (restricted activity; 17 animals per 
50 m2) with ad libitum access to food to 
promote increased fat deposition (obese 
control (OC) group and obese prenatal 
nutrient-restricted (ONR) group) or pas-
ture-grazed (unrestricted activity; 17 ani-
mals per 3,000 m2) with ad libitum access 
to food (lean control (LC) group).
This setup allowed the authors to 
study the interaction of obesity and pre-
natal undernutrition, an unfortunate 
combination that is of growing impor-
tance in many parts of the world.9 A 
strong methodological point is that 
obesity was induced by combination of 
restricted activity with ad libitum access 
to nutrients and that the degree of obes-
ity was very similar in the OC and ONR 
groups. Th e hypothesis of the study was, 
of course, that the metabolic syndrome 
in general, and renal injury in particu-
lar, would be more severe in the ONR 
than in the OC group, because of, for 
instance, impaired nephrogenesis, and 
peripheral insulin resistance secondary 
to adiposity and leptin resistance.9 How-
ever, as compared with the LC group, 
very similar increases were observed in 
blood pressure, heart rate, blood glucose, 
plasma leptin, glomerular fi ltration rate 
(determined by renography), and organ 
weights in both obese groups. Moreover 
— and this is the salient and unexpected 
fi nding — glomerular injury and apop-
tosis in both renal cortex and medulla 
were much more pronounced in the OC 
than in the ONR or LC group. Unfor-
tunately, pasture-grazed lean prenatal 
nutrient-restricted sheep were not stud-
ied, although some data available from 
previous experiments indicate that this 
combination did not have any signifi cant 
eff ects in the kidney.
Th e explanation for these unexpected 
fi ndings is not known. Interestingly, only 
the OC group showed enhanced mRNA 
Figure 1 | A newborn lamb in Peru at an altitude of nearly 4,000 m.
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expression of glucocorticoid and angio-
tensin II receptors and tumor necrosis 
factor-α, but this could all be secondary 
to renal injury. Accumulation of extracel-
lular matrix within the kidney may also 
play a role, as obesity has been shown 
to induce accumulation of hyaluronan 
in the renal medulla of dogs and rab-
bits. External compression of the kidney 
by visceral fat may increase interstitial 
hydrostatic pressure or induce ischemia. 
Such physical changes could also enhance 
sympathetic activity in obesity.10
Apparently, sheep and other ungulates 
have adapted to pregnancy in winter 
when conditions are harsh and nutrients 
scarce. At high altitudes, nutrient restric-
tion and a harsh climate are compounded 
by hypoxia (Figure 1). One aspect of this 
adaptation is undoubtedly the building 
up of reserves in the summer in combi-
nation with a lot of movement all year 
round. A surfeit of nutrients during 
intrauterine life apparently interferes 
with this cycle and caused these sheep 
to lose some unknown protective factor, 
the resulting injury subsequently being 
triggered by obesity. However, in our 
opinion, this peculiar ovine maladjust-
ment is not the most important point of 
the study. 
What is of importance is that, dur-
ing evolution, matching of perina-
tal, juvenile, and adult conditions has 
apparently been a powerful selective 
force.11 Because nowadays life expect-
ancy exceeds our reproductive age and 
modern lifestyle includes excessive cal-
orie and sodium intake, a mismatch of 
these conditions is increasingly appar-
ent and can enhance susceptibility to a 
host of diseases.9,11 Th e observations by 
Williams et al.8 stress that with today’s 
knowledge it remains hard to predict 
the outcome of a specifi c developmental 
perturbation. Clearly, the mechanisms 
remain shrouded but may well include 
metabolic eff ects on genetic imprinting 
that cause persistent eff ects long aft er 
early development.
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Pro-resolution properties of 
macrophages in renal injury
DC Kluth1
Macrophages are inflammatory cells with important roles in the 
propagation of renal injury. More recently they have also been shown 
to be important in the resolution of inflammation. Wang et al. show 
that macrophages can be modulated ex vivo by cytokine stimulation, 
localize to renal tissue, and slow progression of experimental 
glomerular inflammation. Thus strategies targeting macrophage 
function have considerable therapeutic potential.
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Introduction
Macrophage infi ltration is a nearly uni-
versal feature of glomerular injury in both 
human and experimental disease, and the 
presence of macrophages is associated 
with progression to renal failure regard-
less of initiating insult. In general, these 
infl ammatory cells were considered to be 
activated by proinfl ammatory cytokines 
such as tumor necrosis factor-α (TNF-α) 
and interferon-γ and to develop proper-
ties injurious to the kidney. However, it 
has become increasingly clear that macro-
phages are part of a regulated infl amma-
tory system that not only initiates injury 
but is also involved in its resolution.
Wang and colleagues1 (this issue) pro-
vide further evidence of the potential for 
macrophages to have benefi cial eff ects 
in renal injury. Th ey demonstrate that 
in murine adriamycin nephropathy (a 
model of chronic glomerular inflam-
mation), injection of macrophages 
stimulated with the ‘anti-infl ammatory’ 
cytokines interleukin (IL)-4 and IL-
13 reduces the severity of injury for up 
to 3 weeks aft er the injection, whereas 
administration of lipopolysaccharide-
activated macrophages worsens disease. 
Th is further supports the concept that 
administered macrophages may have a 
dominant regulatory eff ect.
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